Enlivex Therapeutics Ltd. announced positive six-month topline data from the Phase IIa stage of its randomized, multi-country Phase I/II Allocetra™ trial (ENX-CL-05-001) in patients with moderate to severe knee osteoarthritis. The results, which have already been presented, indicate that Allocetra™ demonstrated substantial and durable reduction in pain and improvement in function across multiple efficacy endpoints in patients aged 60 and above, compared to placebo. The six-month data reaffirm findings reported at three months and show a robust positive correlation between patient age and the magnitude of clinical effect. Allocetra™ maintained a favorable safety profile through the six-month follow-up. Enlivex plans to initiate a Phase IIb trial evaluating Allocetra™ in age-related primary knee osteoarthritis in the first half of 2026.